Tags

Type your tag names separated by a space and hit enter

[The glycated hemoglobin: indication, interpretation and limitations].
Ann Pharm Fr. 2015 Sep; 73(5):336-9.AP

Abstract

HbA1c is defined by the slow and irreversible binding of glucose to the N-terminal valine of one or both of the beta chains of hemoglobin A (HbA). It is a marker that is becoming increasingly important because of its role in both the diagnosis and monitoring of diabetic patients with type 1 and type 2. It reflects glycemic control of two or three months. Learned societies such as the IFCC and NGSP contributed to its standardization, which allows inter-laboratory comparison of results. Its assay uses chromatographic, electrophoretic or immunochemical methods. The HbA1c concentration is expressed in percent and in mmol/mol, and a number that is between 4 and 6% (20 and 42mmol/mol) is desirable. However, HbA1c cannot be used in some cases and fructosamine assay must be considered.

Authors+Show Affiliations

Laboratoire de biochimie, établissement hospitalier universitaire d'Oran 1(er)-Novembre-1954, BP 4166 Ibn Rochd, Oran, Algérie. Electronic address: z-mustapha2@hotmail.fr.

Pub Type(s)

Journal Article
Review

Language

fre

PubMed ID

25857744

Citation

Zendjabil, M. "[The Glycated Hemoglobin: Indication, Interpretation and Limitations]." Annales Pharmaceutiques Francaises, vol. 73, no. 5, 2015, pp. 336-9.
Zendjabil M. [The glycated hemoglobin: indication, interpretation and limitations]. Ann Pharm Fr. 2015;73(5):336-9.
Zendjabil, M. (2015). [The glycated hemoglobin: indication, interpretation and limitations]. Annales Pharmaceutiques Francaises, 73(5), 336-9. https://doi.org/10.1016/j.pharma.2015.03.001
Zendjabil M. [The Glycated Hemoglobin: Indication, Interpretation and Limitations]. Ann Pharm Fr. 2015;73(5):336-9. PubMed PMID: 25857744.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [The glycated hemoglobin: indication, interpretation and limitations]. A1 - Zendjabil,M, Y1 - 2015/04/06/ PY - 2014/08/20/received PY - 2015/02/19/revised PY - 2015/03/07/accepted PY - 2015/4/11/entrez PY - 2015/4/11/pubmed PY - 2016/12/15/medline KW - Diabetes KW - Diabète KW - Follow-up KW - Fructosamines KW - Glycated hemoglobin KW - HbA(1c) KW - Hémoglobine glyquée KW - Suivi SP - 336 EP - 9 JF - Annales pharmaceutiques francaises JO - Ann Pharm Fr VL - 73 IS - 5 N2 - HbA1c is defined by the slow and irreversible binding of glucose to the N-terminal valine of one or both of the beta chains of hemoglobin A (HbA). It is a marker that is becoming increasingly important because of its role in both the diagnosis and monitoring of diabetic patients with type 1 and type 2. It reflects glycemic control of two or three months. Learned societies such as the IFCC and NGSP contributed to its standardization, which allows inter-laboratory comparison of results. Its assay uses chromatographic, electrophoretic or immunochemical methods. The HbA1c concentration is expressed in percent and in mmol/mol, and a number that is between 4 and 6% (20 and 42mmol/mol) is desirable. However, HbA1c cannot be used in some cases and fructosamine assay must be considered. SN - 0003-4509 UR - https://www.unboundmedicine.com/medline/citation/25857744/[The_glycated_hemoglobin:_indication_interpretation_and_limitations]_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0003-4509(15)00026-7 DB - PRIME DP - Unbound Medicine ER -